Results 41 to 50 of about 385 (131)
The Journal of Physiology, Volume 604, Issue 13, Page 5316-5341, 1 July 2026.Abstract figure legend In this study, we used mathematical modelling to explore the effect of diabetes on muscle mechanoenergetics. Our parameterisation of cross‐bridge models using data from non‐diabetic and diabetic human atrial tissues revealed lower values for cross‐bridge stiffness, detachment rates, attachment rates and lower ATP sensitivity in ...
Julia H. Musgrave +4 more
wiley +1 more source
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
New England Journal of MedicineOne of the major determinants of exercise intolerance and limiting symptoms among patients with obstructive hypertrophic cardiomyopathy (HCM) is an elevated intracardiac pressure resulting from left ventricular outflow tract obstruction. Aficamten is an oral selective cardiac myosin inhibitor that reduces left ventricular outflow tract gradients by ...
Maron, Martin S +32 more
openaire +5 more sources
Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM
Journal of Education, Health and SportBackground: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka +3 more
doaj +1 more source
Journal of Interventional Cardiology, Volume 2026, Issue 1, 2026.Background Percutaneous intramyocardial (PIM) septal pulsed field ablation (SPFA) represents an innovative technique for the management of hypertrophic obstructive cardiomyopathy. However, the paucity of pertinent animal models has impeded comprehensive investigation. This study aimed to assess the safety, efficacy, and feasibility of PIM‐SPFA, as well
Xing-an Zhao +10 more
wiley +1 more source
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
New England Journal of MedicineBeta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited evidence of their efficacy. Aficamten is a cardiac myosin inhibitor that reduces left ventricular outflow tract gradients, improves exercise capacity, and decreases HCM symptoms when added to standard medications.
Pablo Garcia-Pavia +32 more
openaire +3 more sources
Yield of Genetic Testing in Pediatric Cardiomyopathies: Implications for Novel Therapeutic Options
Molecular Genetics &Genomic Medicine, Volume 13, Issue 7, July 2025.Pediatric cardiomyopathies are rare, heterogeneous, and challenging conditions, often with a genetic etiology. We estimated the yield of genetic testing in a pediatric cohort with cardiomyopathies and evaluated the potential candidacy to current or emerging treatments based on genetic results. Over one‐third had a conclusive genetic test, including 25%
Adelaide Ballerini +12 more
wiley +1 more source
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy
JACC: Heart FailureDisopyramide, used in obstructive hypertrophic cardiomyopathy (oHCM) for its negative inotropic properties mediated by its reduction in cytosolic calcium, has been recommended for decades as an option to relieve resistant obstruction. Aficamten is a selective cardiac myosin inhibitor that reduces hypercontractility directly by reducing myosin-actin ...
Ahmad Masri +199 more
openaire +7 more sources
Hypertrophic Cardiomyopathy: Current Perspectives
Reviews in Cardiovascular MedicineHypertrophic cardiomyopathy (HCM) is a multifaceted genetic disorder characterized by left ventricular hypertrophy (LVH) in the absence of alternative causes, with an estimated prevalence ranging from 1 in 200 to 1 in 500 individuals. Since HCM was first
Dhruvil Patel +3 more
doaj +1 more source
International Journal of Clinical Practice, Volume 2025, Issue 1, 2025.Background: Percutaneous transluminal septal myocardial ablation (PTSMA) is one of the invasive therapeutic measures for the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM). Objective: To systematically evaluate the efficacy and safety of PTSMA in patients with HCM.
Sun Qinyu +10 more
wiley +1 more source
Efficacy and Safety of Selective Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: a Meta-analysis [PDF]
Zhongguo quanke yixueBackground Hypertrophic cardiomyopathy (HCM) is a genetic disorder, characterized primarily by left ventricular outflow tract obstruction and asymmetric myocardial hypertrophy, which predisposes to sudden cardiac death and malignant arrhythmias. Although
ZHANG Huijuan, LI Xinghui, ZHANG Xiaoming, YIN Long, SHAO Long
doaj +1 more source